{"id":"W1971365073","doi":"10.2147/btt.s6748","title":"Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib","year":2010,"lang":"en","type":"article","venue":"Biologics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Sunitinib; Sorafenib; Everolimus; Medicine; Internal medicine; Oncology; Renal cell carcinoma; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009101049,0.0001870679,0.0002088614,0.00002384577,0.0001028858,0.00001349986,0.00008073614,0.00007777848,0.0000463795],"category_scores_gemma":[0.00007848185,0.00007778979,0.00004627358,0.00007465057,0.0001450155,0.00003527437,0.00003941453,0.0001632061,0.000003700011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003134774,"about_ca_system_score_gemma":0.00007082254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002157138,"about_ca_topic_score_gemma":0.0002433208,"domain_scores_codex":[0.9991475,0.00001624864,0.0001460607,0.0003259574,0.000110106,0.0002541466],"domain_scores_gemma":[0.9992304,0.0001068062,0.00009259053,0.0003234155,0.0001708694,0.00007592372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02601594,0.001449538,0.908598,0.0004765805,0.0002204549,0.00004331577,0.0008526618,0.000009778032,0.01760475,0.00004234833,0.002710002,0.04197661],"study_design_scores_gemma":[0.006593572,0.004921584,0.8680578,0.00006425956,0.0002383064,0.00001370925,0.00007951398,0.00002466405,0.02375051,0.00004078601,0.09592127,0.0002939589],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963421,0.0003633781,0.00001132263,0.0009898831,0.0001583772,0.00181034,0.00008375453,0.00003421221,0.0002066587],"genre_scores_gemma":[0.9953498,0.00007596783,0.002308902,0.0005762026,0.0001954972,0.0007690833,0.00008370572,0.00002077273,0.0006200199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09321127,"threshold_uncertainty_score":0.3172175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01719074779736497,"score_gpt":0.2452960122209289,"score_spread":0.228105264423564,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}